



PATENT
678503-2001.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : CURIEL *et al.*

Serial No. : 10/697,535

For : INFECTIVITY-ENHANCED CONDITIONALLY-
REPLICATIVE ADENOVIRUS AND USES THEREOF

Filed : OCTOBER 30, 2003

Examiner : SCOTT D. PRIEBE

Art Unit : 1633


745 Fifth Avenue
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV959079518 US

Date of Deposit: September 28, 2006

I hereby certify that this paper or fee is being deposited with the
United States Postal Service "Express Mail Post Office to
Addressee" Service under 37 CFR 1.10 on the date indicated above
and is addressed to: Mail Stop RCE, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450.


(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §§ 1.97(c)(1), (e)(1) AND 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully drawn to the enclosed documents listed on the accompanying PTO Form 1449.

Pursuant to 37 CFR §1.97(c)(1), Applicants request the Examiner to consider this Information Disclosure Statement, and to make of record the documents cited on the

accompanying PTO form 1449 and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Pursuant to 37 CFR §1.97(e)(1), it is hereby stated that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

It is believed that no fees are required by the instant submission as it is accompanied by the statement specified in 37 CFR §1.97(e)(1). However, if any fees are required for this paper, or if any overpayment has been made, please charge Deposit Acct. No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:

Deborah L. Lu
Thomas J. Kowalski
Reg. No. 32,147
Deborah L. Lu
Reg. No. 50,940
Tel. No. (212) 588-0800
Fax No. (212) 588-0500

Based on Form PTO-1449 (3/90)  LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	SERIAL NO.
	678503-2001.1	10/697,535
	APPLICANT	Curiel, et al.
	FILING DATE October 30, 2003	GROUP 1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ	Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P.N., Curiel, D.T., and Alemany, R.: A Conditionally Replicative Adenovirus with Enhanced Infectivity Shows Improved Oncolytic Potency, Clin. Cancer Res., 7:120-126 (2001)
	AR	Barnes, M.N., Coolidge, C.J., Hemminki, A., Alvarez, R.D., and Curiel, D.T.: Conditionally Replicative Adenoviruses for Ovarian Cancer Therapy, Mol. Cancer Ther., 1:435-439 (2002)
	AS	Freytag, S.O., Rogulski, K.R., Paielli, D.L., Gilbert, J.D., and Kim, J.H.: A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy, Human Gene Ther., 9:1323-1333 (1998)
	AT	Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G.N., Khan, Asadullah, Conrad, C.A., Ta-Jen, L., Hong, J., Lemoine, M.G., Suzuki, K., Sawaya, R., Curiel, D.T., Yung, W.K.A., Lang, F.F.: Preclinical Characterization of the Antglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway, J. of the National Cancer Inst., 95(9):652-660 (2003)
	AU	
	AV	

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.